Professor IZUMI Yuishin

 We aim to develop new therapies for neurological disorders that have been considered incurable. We set our sights high and would like to change the world through treatment and research and train medical personnel to realize it. In fact, we have spearheaded a phase Ⅲ clinical trial of ultra-high-dose methylcobalamin for early-stage amyotrophic lateral sclerosis. We have been a forerunner in the research field of dystonia. We discovered novel genes for neurological disorders using a next-generation sequencer. Our policy for medical training is based on the clinical teaching proposed by Sir William Osler.